[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","zmwdhczcqpiu3o1lozwdftwsl","revision",2,"title","Kamada Ltd. 在以色列推出两款新增生物类似药产品","originalTitle","6-K - KAMADA LTD (0001567529) (Filer)","summary","Kamada Ltd. 宣布在以色列推出两款新增产品，以扩展其生物类似药产品组合。该消息作为附件 99.1 随公司 Form 6-K 提交，并被引用纳入其 Form S-8 注册声明。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-06T11:00:28.000Z","discoveredAt","2026-10-06T11:20:12.425Z","timelineAt","category","ai-products","tags",[81,82],"stockSymbols",[80],"score",30,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fst5XT76Ik5Y",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","665e1d73-59aa-49fe-a3d4-96ed86246c9c","Kamada在以色列推出两款新增产品",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the Month of October 2026

Commission File Number 001-35948

Kamada Ltd.

(Translation of registrant’s name into English)

2 Holzman Street
\nScience Park, P.O. Box 4081
\nRehovot 7670402
\nIsrael
\n(Address of principal executive offices)

Indicate by check mark whether the registrant\nfiles or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form\n40-F ☐

This Form 6-K is being incorporated by reference\ninto the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720,\n333-207933, 333-215983,\n333-222891, 333-233267\nand 333-265866.

The following exhibit is attached:

\n \n \n \n \n

99.1

Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

SIGNATURE

Pursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Date: October 6, 2026	KAMADA LTD.

	By:	/s/ Nir Livneh
		\n Nir Livneh \n Vice President General Counsel and Corporate Secretary

EXHIBIT INDEX

\n \n \n \n \n \n \n \n \n

EXHIBIT NO.		DESCRIPTION
99.1		Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel

","zhKind","complete","KMDA","公司与财报","行业与主题","aihot","/items/zmwdhczcqpiu3o1lozwdftwsl","https://www.sec.gov/Archives/edgar/data/1567529/000121390026106968/0001213900-26-106968-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1791504000&sig=503fb7d170765eee","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1791504000&sig=bd7a734cec863d9b 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1791504000&sig=e5a5cfd96e0c1fd2 96w","changelogVersion","2026-10-01T08:00"]